je.st
news
Tag: cancer
Merck advancing breast cancer drug to mid-stage
2014-12-10 23:43:13| Biotech - Topix.net
Drugmaker Merck & Co. said Wednesday that it will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer.
Tags: drug
cancer
breast
breast cancer
New HPV vaccine from Merck strengthens cervical cancer protection
2014-12-10 22:43:17| Biotech - Topix.net
The drugmaker Merck & Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer.
Tags: protection
cancer
vaccine
cervical
The Wall Street Journal: Merck drug shrank tumors in some breast cancer patients in trial
2014-12-10 16:19:02| Biotech - Topix.net
A Merck & Co. drug shrank tumors in about 18.5% of women with an aggressive form of breast cancer in a small clinical trial, an early sign of the potential of immunotherapy to treat breast tumors.
Tags: street
journal
trial
wall
International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
2014-12-10 14:45:00| Merck.com - Research & Development News
Dateline City: SAN ANTONIO Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need SAN ANTONIO--(BUSINESS WIRE)--The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care. Language: English Contact: International Breast Cancer Study GroupLaura Cava Northrop, 617-632-3973press@ibcsg.orgorBreast International GroupCecilia Waldvogel, +41 79 478-0238cecilia.waldvogel@BIGagainstbc.orgorMerckClaire Mulhearn, 908-236-1118claire.mulhearn@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: international
group
study
opening
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
2014-12-10 14:30:00| Merck.com - Corporate News
Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
san
presented
Sites : [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] next »